BioNTech’s African Bet Meets a $17 Billion Cancer Pivot

BioNTech builds Africa's first commercial mRNA plant while racing to become a cancer powerhouse, as Covid revenue fades and co-founders plan exit.

The German biotech is juggling two audacious transformations at once: building Africa’s first commercial mRNA plant while racing to reinvent itself as a cancer powerhouse. Both gambits carry existential weight for a company whose Covid vaccine windfall is rapidly receding.

A €95 Million Gateway to Kigali

Construction is underway in Rwanda’s capital on a modular mRNA factory funded by a €95 million package. The European Commission is contributing a €35 million grant, while the European Investment Bank has offered a credit line of up to €60 million. The facility will rely on BioNTech’s “BioNTainer” units — digital production modules that can be quickly reconfigured to manufacture vaccines targeting malaria, tuberculosis, or future pandemic threats.

The timing is strategic. Africa currently imports roughly 99% of its vaccines, and the African Union has set a target of producing 60% locally by 2040. BioNTech, together with the Coalition for Epidemic Preparedness Innovations (CEPI), has pledged to supply approved candidates for malaria, HIV, and Mpox at affordable prices, prioritizing low- and middle-income countries on the continent.

The Oncology Clock Is Ticking

Parallel to the Africa push, BioNTech is navigating a painful corporate metamorphosis. The company aims to emerge as a multi-product oncology player by 2030, with plans to have 15 active Phase 3 trials in cancer therapy by the end of 2026. Several key data readouts are expected in the second half of this year.

The financial cushion is substantial — roughly €17.2 billion in cash and securities — but the burn rate is accelerating. For the current fiscal year, BioNTech forecasts revenue of around €2 billion, a decline of roughly 25% from the prior year. The company’s management has proposed carrying forward the entire 2025 retained profit of nearly €6.9 billion to fund the transformation.

Wall Street’s Mixed Signals

Analyst sentiment reflects the uncertainty. HC Wainwright recently reaffirmed its buy rating with a $130 price target, citing progress on the bispecific antibody Pumitamig, now in seven Phase 3 trials. Morgan Stanley nudged its target up to $126. The consensus average sits at roughly $133. But Leerink Partners cut its target to $94, pointing to weaker prospects for the drug candidate Gotistobart in an ongoing study.

The stock has recovered from its March trough of €72.50 and now trades near €86 — just above its 50-day moving average of €84.17, but still roughly 16% below its 52-week high.

A Board Reshuffle and a Founder Exit

The annual general meeting on May 15 will mark a turning point. The supervisory board is set to expand from six to eight members, with two new specialists in clinical development and oncology up for election. The move underscores the strategic pivot.

More momentous is the planned departure of co-founders Ugur Sahin and Özlem Türeci, who intend to leave the company by the end of 2026. Their exit, combined with the revenue cliff from declining Covid vaccine sales, creates a leadership vacuum at a critical juncture.

What Comes Next

Before the AGM, BioNTech will report first-quarter results on May 5. Investors will scrutinize how long the existing capital reserves can sustain the research pipeline before oncology products begin to replace lost vaccine revenue. The company has indicated that the next major catalyst will come from oncology data packages due in the second half of 2026.

A lingering legal battle adds another layer of complexity. BioNTech and CureVac continue to pursue royalty claims against Moderna over the Spikevax vaccine, seeking compensation for mRNA patents they argue have been infringed.